Development of targeted drug delivery systems for tumor therapy provides an effective approach to minimize the side effects originating from arbitrary in vivo drug distribution after systemic administration.
Introduction
Cancer is a major public health problem with increasing incidence and mortality.
1,2 While signicant efforts have been made globally for the treatment of cancer over the past 50 years, it still remains the second-leading cause of death worldwide. 3 Although chemotherapeutic agents are commonly used in the clinic to treat cancer, the inevitable side effects have required the improvement of antineoplastic therapies to prolong the survival time of patients in medical intervention. 4 With the development of nanomedicine, the past two decades have witnessed a rapid development of nanotechnology-based drug delivery systems as they provide an alternative therapy for progressive and long-term delivery of therapeutic agents, such as liposomes, micelles, solid lipid nanoparticles (SLNs) or polymeric nanoparticles. 5, 6 The design methodology of novel drug delivery systems is considered to be the key part of targeting and localized delivery of chemotherapy drugs to the cancer tissues. Compared with conventional formulations, the therapeutic agents encapsulated in nanoparticles possess characteristics of desired solubility, enhanced bioavailability and selective biodistribution endowed by their carriers. Among the carriers, the nanoparticles (NPs) prepared from poly (lactide-co-glycolide) (PLGA) have been extensively used due to its biocompatible, biodegradable and nontoxicity, which have also been demonstrated to be advantageous for sustained and controlled drug release with clinical safety. 7, 8 Further modication of such particles with poly (ethylene glycol) (PEG) could enhance the systemic retention, since it can reduce nonspecic protein adsorption, opsonization and subsequent clearance by the reticuloendothelial system (RES). As a result, the improved drug accumulation within tumor tissues can be expected via the enhanced permeability and retention (EPR) effects.
9,10
However, one major limitation of PLGA-NPs is that it cannot differentiate the cancerous cells from normal cells. Recent advances have indicated that the particles with surface modied by targeting ligands, such as aptamers, antibodies, peptides and integrin, could actively internalize into cancerous via ligands/ acceptors (overexpressed on tumor cells) interactions.
11-13
Herein, we focused on a specic type of ligand, namely polyamines (PAs), such as putrescine (PUT), spermine (SPM) and spermidine (SPD), which are small molecular aliphatic amines involved in cell cycle, apoptosis and autophagy.
It is known that various tumor cells, such as neuroblastoma, leukemia, breast cancer, lung cancer and melanomas, overexpress the polyamine transport system (PTS, a specic energydependent transporter or ion channel) on their surface to transport exogenous PAs into cells. 15, 16 It shows that PTS may offer an alternative targeting delivery strategy as PAs (or PAs analogue)-drug conjugates can selectively penetrate into tumor cells via the molecular recognition events involved in polyamine skeleton. An additional benet is that chemical conjugation of PAs could effectively improve the solubility of chemotherapeutics. [17] [18] [19] However, the PTS mediated antineoplastic drug loaded targeting delivery systems have yet been explored. As PAs possess extraordinary binding affinity and specicity to PTS, 20 we reason that PAs-modied NPs holds great potential as a promising vector for anti-tumor therapy. Doxorubicin (DOX), an anthracycline derivative, is one of the most successful rst-line chemotherapeutic anticancer drugs with broad spectrum effectiveness in clinical application against multiple cancers.
21 However, the signicant curative effect of DOX is oen associated with unrestricted biodistribution and undesirable systemic toxicity to healthy tissues. 22, 23 Therefore, the design of targeted DOX delivery systems to inhibit the low bioavailability, rapid drug clearance and serious side effects (such as cardiotoxicity) is critically desired.
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In this study, we utilized SPD, a natural polyamine with moderate chain length and positive charge, as targeting ligand to prepare PAs conjugated, DOX-loaded PEG-PLGA (SPD-DOXNPs) nanoparticles, aiming to actively deliver DOX to cancer cells via the specic binding between SPD and PTS. The constructed SPD-modied nanoparticles were characterized with average particle size, zeta potential, surface morphology, drug encapsulation efficiency (EE), drug loading capacity (LC) and in vitro drug release, respectively. Cellular uptake and in vitro antitumor efficacy of SPD-DOX-NPs for A549 cancer cells were then investigated.
Materials and methods

Materials
Carboxyl-terminated poly(D,L-lactic-co-glycolic acid) (PLGA-COOH) ( SPD-functionalized copolymer SPD-PEG-PLGA was synthesized by conjugating Boc-SPD to PLGA-PEG-COOH. Briey, PLGA-PEG-COOH (2 g, 0.1 mmoL) was activated by above EDC/ NHS system for 12 h. Aer puried and dried, the PLGA-PEG-NHS (1 g, 0.05 mmoL) dissolved in DCM (4 mL) was followed by the addition of DIEA (26 mg, 0.2 mmoL) and Boc-SPD (26 mg, 0.075 mmoL) dissolved in DCM (2 mL) in a drop-wise manner with gentle stirring. The reaction was carried out for 24 h under nitrogen atmosphere and the resultant solution was precipitated and repeatedly washed in ice-cold diethyl and diethyl ether-methanol (7/3, v/v). Aer dried, the block copolymer dissolved in DCM (4 mL) was mixed with triuoroacetic acid (TFA, 1 mM) and adjusted the pH to 8 with a saturated sodium bicarbonate solution to remove of BOC protection. The nal SPD-PEG-PLGA block copolymer was dried and stored at À20 C until use.
The 1 H NMR spectra of the PEG-PLGA and SPD-PEG-PLGA were recorded at RT using a Bruker Avance 400 MHz NMR spectrometer (Varian, USA) to verify PEG and SPD coupling occurred.
Preparation of nanoparticles
SPD-PEG-PLGA nanoparticles loaded with DOX (SPD-DOXNPs) were prepared by the emulsication-solvent evaporation method. 25, 26 Briey, SPD-PEG-PLGA (35 mg) and DOX (1.75 mg) were dissolved in 1 mL DCM. The organic phase was mixed with 2% PVA aqueous solution (4 mL) and emulsied by sonication (120 W, 3 min) on ice bath using probe sonication (Emerson Electric Holding, USA). The resulted O/W emulsion was further stirred at 30 C for 4 h to evaporated the organic solvent (Scheme 1). The redundant materials and free molecules were removed by centrifugation (20 000g, 4 C) for 30 min and then resuspended in PBS buffer (pH 7.4) to obtain a nal desired concentration for further use. The DOX-loaded PEG-PLGA nanoparticles (DOX-NPs) were prepared with the same procedure except PEG-PLGA for carrier material.
Characterization of nanoparticles
2.4.1 Particle size, zeta potential and morphology. Particle size and zeta potential of DOX-NPs and SPD-DOX-NPs were determined by dynamic light scattering (DLS) analysis using Malvern Zeta Sizer Nano series (Nano ZS, Malvern Instruments, UK). The morphology of nanoparticles were investigated by transmission electron microscopy (TEM, Titan G2 60-300, FEI, USA) aer sample suspended in water and then dropped into Formvar-coated copper grids.
Drug entrapment efficiency (EE) and loading capacity (LC).
For determining the drug entrapment efficiency (EE) and loading capacity (LC) of NPs, the nanoparticles were resuspended and ultrasonicated in methanol for 20 min aer separated by centrifugation (20 000g) for 30 min. Another aliquot of the nanoparticles suspension was quantitated to determine the total DOX concentration. The DOX was determined by HPLC (LC 2010A, Shimazu, Japan) using an ODS C 18 (200 Â 4.6 mm, 5 mm, Diamonsil, Beijing, China) column with sodium lauryl sulfate (SDS) solution (contain 1.36 mL L À1 phosphoric acid)-: acetonitrile : methanol (50/50/6, v/v) as the mobile phase at the ow rate of 1.0 mL min
À1
. The column temperature was maintained at 40 C, sample injection volume was 20 mL and the detection wavelength was 223 nm. The EE and LC were calculated using the following formulas: , 350 mL) for 20 min. And then the samples were analyzed by uorescence spectrophotometer (RF5301, Shimadzu, Japan) (l ex : 390 nm, l em : 480 nm). The control was used the same approach as described above without NPs. The SPD contents on NPs surface were plotted as a function of the molar quantities of SPD/weight of NPs.
2.4.4
In vitro drug release. The in vitro release behavior of DOX from SPD modied nanoparticles was studied by the membrane diffusion method. Briey, 1.0 mL of free DOX solution, DOX-NPs or SPD-DOX-NPs was put into a dialysis bag (MWCO: 3400) and then immersed into 20 mL dissolution medium (PBS 7.4) in a thermostatic shaker vibrated horizontally at 100 rpm and 37 C. 1 mL dissolution medium was taken out for HPLC analysis aer dialysis 1, 2, 3, 4, 6, 12, 24, 48, 72, 96, 120, 144, 168, 192 h and an equal volume of fresh PBS was added immediately.
Cell culture
A549 cells were cultured in DMEM complete medium (containing 10% (v/v) FBS and 1% penicillin/streptomycin (100 U mL À1 )) at 37 C in a humidied atmosphere with 5% CO 2 , and subcultivated every 2-3 days at 80-90% conuence and digested with 0.25% trypsin-EDTA at a split ratio of 1 : 2.
2.6
In vitro cellular uptake study respectively. Then A549 cells were washed thrice with cold PBS and treated with 4% paraformaldehyde at room temperature for 20 min and subsequently stained with 500 mL of DAPI (1 mg mL À1 ) for 10 min. Aer rinsed thrice with PBS, the uptake of various DOX formulations were nally visualized by uores-cence microscope (Ti-S, Nikon, Japan). For quantitative cellular uptake experiment, A549 cells were seeded in six-well culture plate at the density of 2 Â 
In vitro antitumor activity evaluation
The in vitro antitumor activity of the NPs was evaluated using an MTT assay. A549 cells were seeded and cultured in 96-well plate at the density of 4 Â ) solution was added to each well and cells were incubated for another 4 h. The MTT containing media were removed and 100 mL DMSO was added to dissolve the formazan crystals. The plate was shaked for 10 min at room temperature. Absorbance was measured at 490 nm with the multimode reader (Innite M200, Tecan, CH) and the cell inhibition ratio was calculated.
Statistical analysis
All the experiments were performed in triplicate and data was indicated as mean AE SD. One-way analysis of variance was used to determine the statistical signicance of differences among multiple groups. And a P-values <0.05 were considered to be statistically signicant.
Results and discussion
Synthesis and characterization of SPD-PEG-PLGA copolymer
SPD-PEG-PLGA copolymer was synthesized via an EDC/NHS technique. 29 Briey, PLGA-COOH was rstly transformed into PLGA-NHS and then reacted with NH 2 -PEG-COOH. The resultant PLGA-PEG-COOH was subsequently activated and conjugated with Boc-SPD, and the t-butyloxy carbonyl was removed in the presence of TFA to obtain SPD-PEG-PLGA (Fig. 1A) . The successful synthesis of SPD-PEG-PLGA was conrmed by 1 H NMR spectrum (Fig. 1B) . The sharp peak at 3.6 ppm belonged to the methene (-CH 2 ) proton of PEG chain. The characteristic peaks at 1.6, 4.8 and 5.2 ppm were attributed to the methyl (-CH 3 ), methine (-CH) and methene (-CH 2 ) protons in PLGA segment, respectively. And the peak at 1.4, 1.5, 1.7 and 2.7 ppm were assigned to methene (-CH 2 ) protons in SPD chains. The sharp peak of PEG at 3.6 ppm and the characteristic peaks of SPD at 1.4 and 1.5 ppm on product demonstrated the successful synthesis of SPD-PEG-PLGA copolymer.
FTIR spectra conrmed the compositions of synthesized polymer (Fig. 1C) . The characteristic bands at 3438 and 2886 cm À1 were attributed to -OH, -NH 2 and C-H stretching vibration, respectively, and the sharp bands at 1466 and 1113 cm
À1
were C-H deformation vibration and C-O-C absorption of NH 2 -PEG-COOH (Fig. 1C, trace a) . The band at 1758 cm À1 belonged to carbonyl group of PLGA-COOH (Fig. 1C, trace b) , which was also observed in PEG-PLGA copolymer. The absorption bands at 1635 and 1392 cm À1 of amide unit conrmed the successful conjugation of PEG with PLGA (Fig. 1C, trace c) . Moreover, the infrared spectra at 1758-1759 cm À1 (C]O stretch), 1177-1133 and 1096-1091 cm À1 (C-O and C-C stretch) of PEG-PLGA polymer exhibited shiing and intensity increase upon SPD functionalization (Fig. 1C , trace e). The bands changes were attributed to the hydrophilic interactions of primary amine groups in polyamine with PEG-PLGA polymer skeleton.
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Preparation and characterization of nanoparticles
DOX-loaded nanoparticles was prepared by a typical emulsication-solvent evaporation method (Scheme 1). Briey, the drug and synthesized polymers were rst dissolved in DCM and quickly added into the aqueous phase. The O/W emulsions were transformed into uniform nano-droplets under probe sonication and evaporated the solvent to get stable nanoparticles. The as-prepared nanoparticles were characterized for the hydrodynamic size, polydispersity and zeta potential. Both the average diameter of DOX-NPs and SPD-DOX-NPs were about 151 nm with homogenous size distribution observed by DLS (PDI < 0.1, Fig. 2A and B) . The morphology of the NPs was then characterized by transmission electron microscope (TEM). As showed in Fig. 2A and B, DOX-NPs or SPD-DOX-NPs exhibited relatively monodispersed spherical shapes with a uniform size and a smooth surface. The intact morphologies of nanoparticles provided a stable carrier support for drug encapsulation. Notably, the size of DOX-loaded NPs determined by TEM was slightly smaller than that measured by DLS, which could be ascribed to the swelling or stretching of the SPD-PEG chain in solution for DLS measurement, while shrinking and crimping on the copper grid surface during drying and vacuumizing for TEM characterization.
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The zeta potential of DOX-NPs was observed to be about À5.2 mV. Aer SPD modication, the zeta potential of SPD-DOX-NPs was characterized to be nearly À2.4 mV. The decreased negative charge can be attributed to the fact that the electropositive SPD partly screened the negatively charged carboxyl groups tails on PEG-PLGA polymer. The EE and of LC of optimized DOX-NPs were calculated to be 56.4% and 0.83%, respectively. For SPD-DOX-NPs, a slightly decreased EE and LC were observed to be 50.1% and 0.78%, respectively. This may be due to the increased hydrophilicity of PLGA-PEG block copolymer aer terminal conjugated with spermidine (SPD) hydrophilic chain, and the hydrophobic DOX tended to diffuse from nanoparticles to aqueous solvent due to the reduced binding affinity of DOX with SPD-PEG-PLGA during SPD-DOX-NPs preparation.
The amount of SPD on nanoparticles surface was determined by a uorescamine-based assay (Fig. S1A †) . In this assay, the uorescamine agent could generate a uorescent compound (l ex : 390 nm, l em : 480 nm) in the presence of primary amine at pH 9.0 with extremely high sensitivity on the pM scale, while the excess reagents generate hydrolysis products with nonuorescent. 34 As showed in Fig. S1B and C, † the uores-cence intensity of uorescamine at 480 nm was linear correlation with the concentration of Boc-SPD. Based on the calibration curve, the surface SPD content was measured to be 46.4 mmoL g À1 .
In vitro drug release
In vitro drug release of DOX from DOX-loaded NPs at 37 C was evaluated by a dialysis method at pH 7.4 for up to 192 h incubation. As showed in Fig. 2C , about 90% free DOX diffused to release medium within 4 h and almost released totally aer 6 h. While DOX released from DOX-NPs or SPD-DOX-NPs revealed a remarkably slower release, and the two nanoparticles exhibited a similar release behaviors during the whole experiment period. An initial burst of DOX release from DOXNPs or SPD-DOX-NPs was observed in the rst 12 h ($50%) due to a large amount of drug adsorbed on the surface of NPs. Aer the sudden release period, the release of DOX from NPs was sustained over following 192 h (Fig. 2D) . In addition, a series of SPD-PEG-PLGA polymers with different SPD contents from 20 to 60 mmoL g À1 have also been synthesized to prepare SPD-DOX-NPs (Table 1 ). The cumulative release of DOX from SPD-DOX-NPs was gradually decreased with increased SPD contents (Fig. S2 †) . This can be explained by that terminal carboxyl groups of PEG chains are more labile to hydrolysis than that of amide bonded SPD chains, leading to faster erosioncontrolled drug release from NPs. The phenomenon was also observed in Fig. 2C and D, as the cumulative release of DOX from DOX-NPs (nearly 75%) was signicantly increased compared with that of SPD-DOX-NPs (nearly 61%) in 192 h.
Cellular uptake of DOX loaded nanoparticles
The uorescence microscope was used to visualize the cellular uptake of free DOX and DOX loaded nanoparticles by A549 cells at an equivalent 5 mg mL À1 of DOX. The cells were imaged in the red channel for DOX and the blue channel for the nuclear stain. Among various groups, the brightest uorescence was observed when A549 cells were incubated with SPD-DOX-NPs (Fig. 3A-C) , indicating that the modication of SPD on the nanoparticles surface facilitates the cellular uptake of NPs. By contrast, free DOX solution exhibited weak uorescence and DOX-NPs with only moderate uorescence. Quantitative evaluation of cellular uptake of various groups was performed by ow cytometry aer 1 h incubation. As showed in Fig. 3D and E, the uorescence intensity of SPD-DOX-NPs was signicantly enhanced compared to free DOX (P < 0.01) or DOX-NPs (P < 0.05), indicating the active uptake of SPDmodied NPs via affinity binding with PTS overexpressed on A549 cells surface. Meanwhile, though the cellular uptake of DOX-NPs was attributed to the endocytosis of NPs and free diffusion of DOX adsorbed on NPs surface, leading the mean uorescence intensity of DOX-NPs enhanced $1.1 fold compared with that of free DOX, the cellular uptake of DOX-NPs by passive targeting was not signicantly stronger than free DOX (P > 0.05).
Pretreatment with SPD or DFMO
To conrm that the enhanced cellular uptake of SPD-DOX-NPs was due to its surface SPD modication, two parallel experiments were design. In the rst experiment, the A549 cells were pre-treated with free SPD for 30 min so that the PTS on tumor cells surface was blocked. In this case, the specic enhancement effect of SPD-DOX-NPs can be abolished if PTS was important for particle uptake. Otherwise, the free SPD pretreatment would not have much effect on particle internalization. As showed in Fig. 4A and B, the mean uorescent intensity of A549 cells incubated with DOX-NPs was similar to treated cells with free SPD prior to the addition of NPs. While the internalization efficiency of SPD-DOX-NPs was reduced since the PTS binding sites was gradually occupied by free SPD. And the competitive effect was almost saturated when the amount of free SPD up to be 0.5 mg mL À1 .
In the other experiment, the cells were pre-treated with DFMO, a commonly used reagent to up-regulate the cell uptake of exogenous polyamines. As showed in Fig. 4C and D, the cell uptake of DOX-NPs changed lowness aer pretreatment of DFMO due to its passive transport. By contrary, the mean uorescent intensity of A549 cells incubated with SPD-DOXNPs was increased signicantly (P < 0.05) aer DFMO preconditioning for 24 h. In fact, DFMO was as a suicide inhibitor of ornithine decarboxylase (ODC), one of the key enzymes involved in polyamine biosynthesis. 35, 36 The PTS activity of cancer cells was usually upregulated to replenish depleted intracellular polyamine pools, 37,38 leading more SPD-DOX-NPs transported into cells. However, the internalization efficiency reduced slightly due to the affection of cell viability when the amount of DFMO over 50 mM (Fig. S3 †) . Taken together, the parallel experiments of SPD and DFMO pretreatment suggested that SPD-DOX-NPs was transported into cancer cells by a PTSmediated endocytosis process.
The cellular uptake of NPs with various surface SPD contents
In order to investigate the effect of SPD density on cellular uptake efficiency, we synthesized SPD-PEG-PLGA polymers with different SPD contents from 20 to 60 mmoL g À1 . As
shown in Table 1 , the variation of SPD contents had little impact on the particle size, drug-encapsulation ration and carried amount. Since the terminal carboxyl was reacted with the positive charge of polyamine skeleton, the zeta potential of SPD-NPs was near to neutrality with the improvement of SPD contents. Aer co-cultured with A549 cells for 1 h, the uorescence intensity of the cells increased with the raise of SPD contents (Fig. 5A) . Meanwhile, the relative uorescent intensities of SPD-DOX-NPs with different SPD contents were normalized by that of non-SPD DOX-NPs. As shown in Fig. 5B , higher SPD content resulted in relatively stronger uorescence intensity, indicating that SPD modication facilitates the internalization of NPs into A549 cells via SPD bound to the PTS overexpressed on the surface of cancer cells. However, the targeting ability of SPD was weakened with the SPD contents over 50 mmoL g À1 . It was presumably caused by the affinity between conjugated SPD and PTS was reduced by the steric hindrance of nanoparticles, or the active sites of SPD were saturated with targeted NPs. These results indicated that the cellular internalization of SPDmodied NPs was receptor-dependent for anti-cancer therapy. 
In vitro cytotoxicity
The ow cytometry analysis showed that the uptake of nanoparticles increased by PTS-overexpressing tumor cells aer SPD modied on NPs surface. However, the antitumor activity is undened. To understand the effects of this targeted drug delivery system on cancer cell proliferation, the in vitro antitumor efficacy of various DOX formulations was evaluated in A549 cells by MTT assay. Blank NPs or SPD-NPs did not exhibit obvious cytotoxicity at high concentration of 4 mg mL À1 (Fig. S4 †) , suggesting that the polymer delivery carriers possess satisfactory biocompatibility, and that cytotoxicity of DOXloaded NPs was mostly caused by the encapsulated drug. As shown in Fig. 6A , the growth inhibition of A549 cells was increased apparently in a concentration-and formulationdependent pattern. As a control, the IC 50 value of free DOX was 1.13 AE 0.11 mg mL À1 . DOX-loaded SPD-free NPs revealed similar cytotoxicity with IC 50 0.89 AE 0.16 mg mL À1 compared to free DOX for A549 cells (P > 0.05). Meanwhile, the toxicity of SPD-DOX-NPs increased gradually with rising contents of surface SPD. At the highest SPD contents, the cytotoxicity reached 1.6-fold and 2.0-fold compared the SPD-free and free DOX formulation, respectively (Fig. 6B) . Overall, PTS-mediated binding and internalization of SPD-NPs have been proposed to enhance the cancer cells proliferation inhibition of anticancer therapeutic agents. In fact, PTS was highly overexpressed in multiple tumor cells, implementation of PTS as a targeting site was a potential strategy for targeted delivery of chemotherapeutic agents into tumor cells. In this study, SPD, with moderate positive charge and chain length, was rst exploited as a targeting ligand in a PEG-PLGA nanoparticle-based DOX delivery system. Since SPD exhibited high binding affinity to PTS, such a SPD-PEG-PLGA delivery system may have the potential to improve the delivery of DOX to cancer cells. Our results suggested that SPD-DOX-NPs could actively targeting to cancer cells and offer an effective antitumor efficiency compared to free DOX and DOX-NPs. 
Conclusion
In this work, DOX-loaded SPD-PEG-PLGA nanoparticles were constructed and characterized. The NPs formulation was uniform spherical with sustained drug release prole, enhanced cellular uptake and thereby cytotoxicity in a concentration dependent manner with SPD contents on NPs surface. All of these results suggested that these SPD modied PEG-PLGA nanoparticle-based drug delivery system might be a promising drug carrier for targeting treatment strategy of cancers.
